YPO: Only One in 25 Small and Medium-sized Business Leaders Say They Measure Company Carbon Emissions
Lack of measurement of environmental and energy performance among small and medium-sized businesses (SMBs) hampering ability to contribute to the energy transition and tackle climate change 96% of SMB leaders said they do not measure scope 1-3 carbon emissions and 95% do not have data on the level o
Commercial Vehicle Propeller Shaft Market to Record USD 3.74 billion Growth between 2023 to 2027, Market Share, Trends, Drivers, and Opportunity Assessment – Technavio
NEW YORK, Jan. 30, 2024 /PRNewswire/ — The commercial vehicle propeller shaft market is estimated to grow at a CAGR of 4.64% by USD 3.74 billion from 2023 to 2027, according to Technavio. The increasing demand for commercial vehicles is notably driving growth. The growth is due to increase
Shandong Heavy Industry Group Agreement with Singapore’s Jardine Cycle & Carriage Direct Motor Interests for 120 Zhongtong Bus New Energy Buses
JINAN, China, Jan. 31, 2024 /PRNewswire/ — In a significant ceremony held in Singapore on January 25, Shandong Heavy Industry Group and Singapore’s Jardine Cycle & Carriage Direct Motor Interests (DMI) formally inked a deal for 120 Zhongtong Bus new energy buses. Zhongtong Bus new en
SKYPlay, Blockchain Solutions Development through Collaboration with MetaQ
SEOUL, South Korea, Jan. 31, 2024 /PRNewswire/ — On January 17th, SKYPlay announced that it has signed a business agreement with MetaQ, a specialized blockchain company, to collaborate on business initiatives. MetaQ is a company that provides services such as blockchain-based online content a
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy – – If approved, PADCEV with KEYTRUDA would be the first combination in Japan to offer an alternative to chemotherapy,
Study Abroad at Chulalongkorn University: A Gateway to World-Class Education in Asia
BANGKOK, Jan. 31, 2024 /PRNewswire/ — Poised to become one of Asia’s educational hubs, Chulalongkorn University is admitting Thai and international students to more than 100 international programs in all disciplines to create learning experiences without borders and prepare graduates f
SourceFuse Achieves the 100 AWS Certifications Distinction
JACKSONVILLE, Fla., Jan. 30, 2024 /PRNewswire/ — SourceFuse, a strategic digital transformation company helping businesses evolve through cloud-native technologies, has collectively achieved more than 100 Amazon Web Services (AWS) Certifications. AWS recognized the achievement by awarding Sou
Ransomware-as-a-Service, Supply-chain Attacks, Geopolitical Issues Complicate OT/ICS Cybersecurity for Global Industries, TXOne Networks Report Reveals
Findings illustrate need for Cyber-Physical Systems Detection and Response for combatting both known and unknown threats TAIPEI, Jan. 31, 2024 /PRNewswire/ — TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, published its 2023 annual report detailing a growing range of cyber
Dry Shampoo Market: 33% of Market Growth is Expected in North America by 2027 – Technavio
NEW YORK, Jan. 30, 2024 /PRNewswire/ — The dry shampoo market is estimated to grow by USD 1.90 billion from 2023 to 2027, according to Technavio. The market is estimated to grow at a CAGR of 12.03% during the forecast period. However, the growth momentum will progress. North America is estima
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. – NEO
NEW YORK, Jan. 30, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ex
